PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.
IPO Year: 2016
Exchange: NASDAQ
Website: pavmed.com
Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK, March 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced a campaign, entitled "Embrace the Future", designed to showcase its groundbreaking EsoCheck® Esophageal Cell Collection Device, with Collect+Protect™ Technology, to gastroenterologists and the broader medical community. The campaign will coincide with Esophageal Cancer Awareness Month this April and will be prominently featur
Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet Conference call and webcast to be held today, March 25th, at 8:30 AM EDT NEW YORK, March 25, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital
Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24 New sales channel generated over 20 new cash-pay concierge medicine contracts Secured first agreement to pay for EsoGuard under state biomarker legislation Conference call and webcast to be held today, March 24th at 8:30 AM EDT NEW YORK, March 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), today provided a business update for the Company and reported financial results for the four
Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy NEW YORK, March 20, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that a recent update to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) focused on Esophageal and Esophagogastric Junction Cancers (Version 1.2025) has added a new section on esophageal precancer (Barrett's Esophagus or BE) screening. The
Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK, March 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that its ENVET-BE clinical utility study has been accepted for publication in Gastroenterology & Hepatology—the fifth peer-reviewed publication of clinical utility data for Lucid's EsoGuard® Esophageal DNA Test, and the second to present findings from a real-world screening population. The manuscript, entitled Enhancing th
Regional Blue Cross Blue Shield plan will cover non-invasive screening of esophageal precancer and cancer NEW YORK, March 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that Highmark Blue Cross Blue Shield, an independent licensee of the Blue Cross and Blue Shield Association, has issued a positive coverage policy for non-invasive screening of esophageal precancer and cancer in New York state. The new policy will cover Lucid's EsoGuard® Esophageal DNA Test in patients who meet established criteria for esophageal precancer te
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, March 11, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, March 25, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the C
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Monday, March 24, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth quarter 2024 finan
NEW YORK, March 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the closing of its previously announced registered direct offering of 13,939,331 shares of common stock at a purchase price of $1.10 per share. The gross proceeds to the Company from this offering are approximately $15.3 million, before deducting the approximately $0.8 million in placement agent's fees and other offering expenses payable by the C
NEW YORK, March 4, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it has entered into subscription agreements with certain accredited investors to sell 13,939,331 shares of common stock at a purchase price of $1.10 per share in a registered direct offering. The gross proceeds to the Company from this offering are expected to be approximately $15.3 million, before deducting the approximately $0.8 million in placement agent's fees and other offering expenses payable by the Company.
8-K - PAVmed Inc. (0001624326) (Filer)
10-K - PAVmed Inc. (0001624326) (Filer)
8-K - PAVmed Inc. (0001624326) (Filer)
8-K - PAVmed Inc. (0001624326) (Filer)
8-K - PAVmed Inc. (0001624326) (Filer)
D - PAVmed Inc. (0001624326) (Filer)
S-8 - PAVmed Inc. (0001624326) (Filer)
S-8 - PAVmed Inc. (0001624326) (Filer)
8-K - PAVmed Inc. (0001624326) (Filer)
8-K - PAVmed Inc. (0001624326) (Filer)
3 - PAVmed Inc. (0001624326) (Issuer)
4 - PAVmed Inc. (0001624326) (Issuer)
4 - PAVmed Inc. (0001624326) (Issuer)
3 - PAVmed Inc. (0001624326) (Issuer)
4 - PAVmed Inc. (0001624326) (Issuer)
4 - PAVmed Inc. (0001624326) (Issuer)
4 - PAVmed Inc. (0001624326) (Issuer)
4 - PAVmed Inc. (0001624326) (Issuer)
4 - PAVmed Inc. (0001624326) (Issuer)
4 - PAVmed Inc. (0001624326) (Issuer)
Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet Conference call and webcast to be held today, March 25th, at 8:30 AM EDT NEW YORK, March 25, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital
Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24 New sales channel generated over 20 new cash-pay concierge medicine contracts Secured first agreement to pay for EsoGuard under state biomarker legislation Conference call and webcast to be held today, March 24th at 8:30 AM EDT NEW YORK, March 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), today provided a business update for the Company and reported financial results for the four
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, March 11, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, March 25, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the C
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Monday, March 24, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth quarter 2024 finan
Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage Veris Health completes pilot program with The Ohio State's James Cancer Hospital and continues pursuit of financing to relaunch development of implantable monitor Ongoing initiatives position PAVmed to preserve Nasdaq listing Conference call and webcast to be held today, November 14th at 8:30 AM EST NEW YORK, Nov. 14, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provide
EsoGuard® revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initiative expanded to multiple programs to drive near-term revenue growth Conference call and webcast to be held today, November 13th at 8:30 AM EST NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), today provided a business update for the Company and presented financial results for the three months ended September 30, 2024.
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, Oct. 31, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, November 14, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa
Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, Oct. 30, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, October 13, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's third quarter 2024 fin
Lucid reports record quarterly EsoGuard® test volume and held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's MolDX Program Veris Health actively pursuing financing following launch of pilot program with The Ohio State's James Cancer Hospital Conference call and webcast to be held today, August 13th at 8:30 AM EDT NEW YORK, Aug. 13, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ:LUCD) ("
EsoGuard® test volume increased 31 percent quarterly; 44 percent annually Clinical data now well-positioned for final push towards broad coverage and reimbursement Over 50 high-volume #CheckYourFoodTube Precancer Testing Events in 2Q24, including first with upfront contracted payment Conference call and webcast to be held today, August 12th at 8:30 AM EDT NEW YORK, Aug. 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three months end
Cantor Fitzgerald initiated coverage of PAVmed with a rating of Overweight and set a new price target of $8.00
Lake Street Capital reiterated coverage of PAVmed with a rating of Buy and set a new price target of $9.00 from $5.00 previously
SC 13G - PAVmed Inc. (0001624326) (Subject)
SC 13G - PAVmed Inc. (0001624326) (Subject)
SC 13G - PAVmed Inc. (0001624326) (Subject)
SC 13G - PAVmed Inc. (0001624326) (Subject)
SC 13G/A - PAVmed Inc. (0001624326) (Subject)
Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements. As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain
Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing
The incubator, PMX, and medical device firm Hatch Medical, execute joint venture agreement to complete their development and commercialization, starting with PortIO NEW YORK, March 21, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has launched a wholly owned incubator, PMX, to complete development and commercialization of existing portfolio technologies, including the PortIO™ Implantable Intraosseous Vascular Access Device ("PortIO"), EsoCure™ Esophageal Ablation Device ("EsoCure"), and CarpX® Minimally Inva
Manning Brings Vast Digital Health Experience Focused on Demonstrable Growth and Commercial Excellence NEW YORK, April 25, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced the appointment of Gary Manning to the newly created position of President, Veris Health. Mr. Manning reports directly to Lishan Aklog, M.D., PAVmed's Chairman & Chief Executive Officer and Veris' Executive Chairman.
PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of Shaun O'Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O'Neil has served as PAVmed's Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will serve on the Company's Executive Committee and as an executive officer pursuant to Section 16(a) of the Securities
PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of prominent healthcare services industry leader and president of Care Solutions for Evernorth, Joan Harvey, to its Board of Directors. Ms. Harvey will serve as a member of the Company's Audit and Compensation Committees. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220215005417/en/PAVmed appoints Joan Harvey to its Board of Directors. (Photo: Business Wire) "Ms. Harvey brings a wealth of h
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) ("PAVmed"), today announced the appointment of highly accomplished molecular biologist Suman M. Verma, M.D., Ph.D. as Lucid's Chief Scientific Officer and PAVmed's VP, Molecular Diagnostics. "I am very pleased to welcome Dr. Verma to the Lucid Diagnostics team," said Lishan Aklog M.D., Lucid's Chairman and Chief Executive Officer. "In her role as VP of Genomic Services at our CLIA laboratory partner, ResearchDx, Dr. Verma played a central role in transferring the EsoGuard® Esophageal DNA Test from the Case Western Reserve Uni
Global Industry Executive Plans to Leverage On-Site Healthcare Services Experience to Help Drive Growth and Continued Excellence in Service Delivery Angeles Equity Partners, LLC ("Angeles"), a private investment firm focused on value creation through operational transformation, today announced the appointment of Debbie White to the Board of Directors of Xanitos. Naming Ms. White to the Board adds an experienced industry executive to help steer Xanitos' strategic plan to become the premier specialty provider of environmental services (EVS), patient transport, and linen services to hospitals and other acute care settings nationwide. This press release features multimedia. View the full relea
NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent global technology industry leader Tim Baxter, to its Board of Directors. Mr. Baxter will serve as Chair of the Company's Nomination Committee and as a member of its Audit Committee. "I am very pleased to welcome Tim Baxter to PAVmed's Board of Directors," said Lishan Aklog M.D., PAVmed's Chairman and Chief Executive Officer. "Mr. Baxter is among the most accomplished and respected executives in the technology industry. His long and distinguished caree